KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBITDA (2020 - 2025)

Historic EBITDA for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Q3 2025 value amounting to -$80.4 million.

  • Ginkgo Bioworks Holdings' EBITDA fell 4777.0% to -$80.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$337.8 million, marking a year-over-year increase of 4787.05%. This contributed to the annual value of -$550.3 million for FY2024, which is 3807.96% up from last year.
  • Ginkgo Bioworks Holdings' EBITDA amounted to -$80.4 million in Q3 2025, which was down 4777.0% from -$57.8 million recorded in Q2 2025.
  • Ginkgo Bioworks Holdings' 5-year EBITDA high stood at -$26.7 million for Q3 2021, and its period low was -$1.7 billion during Q4 2021.
  • Over the past 5 years, Ginkgo Bioworks Holdings' median EBITDA value was -$168.9 million (recorded in 2024), while the average stood at -$297.9 million.
  • Per our database at Business Quant, Ginkgo Bioworks Holdings' EBITDA tumbled by 291448.43% in 2021 and then skyrocketed by 9004.0% in 2022.
  • Over the past 5 years, Ginkgo Bioworks Holdings' EBITDA (Quarter) stood at -$1.7 billion in 2021, then surged by 90.04% to -$167.8 million in 2022, then dropped by 23.55% to -$207.3 million in 2023, then skyrocketed by 47.13% to -$109.6 million in 2024, then increased by 26.63% to -$80.4 million in 2025.
  • Its EBITDA was -$80.4 million in Q3 2025, compared to -$57.8 million in Q2 2025 and -$90.0 million in Q1 2025.